Abivax $920 million cash haul lets it prepare for solo U.S. launch instead of relying on a buyer, CEO tells CNBC
Story
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.
Its latest fundraising round provides the French biotech with enough cash to finance operations through 2029.